Profluent has closed a significant $106 million financing round. This capital injection accelerates the company’s mission to make biology fully programmable.
The co-leading investors are Altimeter Capital and Bezos Expeditions. This new funding brings Profluent’s total raised capital to $150 million since its founding.
Existing backers, including Spark Capital, Insight Partners, and Air Street Capital, also participated in this substantial offering. The capital will fuel the expansion of their frontier AI models targeting protein design applications.
Profluent is focused on transforming drug development, diagnostics, agriculture, and biomanufacturing through novel molecular creation. They are pioneering the use of large-scale language models specifically for generating functional proteins.
The company has already established key scientific benchmarks, including creating the first AI-designed CRISPR system from scratch. Furthermore, their proprietary Protein Atlas now contains over 115 billion unique protein sequences, representing the world's largest such data resource.
This validated technology is already deployed across the industry. Profluent’s open-source gene editor, OpenCRISPR-1, is actively utilized by major pharmaceutical firms and academic researchers globally.
Commercial momentum is strong, evidenced by partnerships with entities like Revvity and Corteva Agrisciences. This traction underscores the market's readiness for AI-authored biological solutions.
The company is aggressively expanding beyond genome editors into designing complex molecules like antibodies and specialized enzymes. CEO Ali Madani stated this funding speeds the path from laboratory breakthrough to widespread real-world utility.
This investment solidifies Profluent's position at the intersection of deep tech and life sciences. They are positioning themselves as the foundational partner for industries seeking bespoke, AI-optimized biological tools.
